Evexia Lifecare Ltd (524444)
🎯 Key Takeaways
- Evexia Lifecare Ltd appears to be in a prolonged phase of financial stagnation and operational underperformance, with no meaningful revenue or profit growth over the past year and persistently low returns on capital. Management commentary from recent filings indicates routine operational updates and shareholder approvals but no strategic inflection points.
- Revenue declined 16% QoQ to ₹31 in Q1FY27.
- ⚠️ Chronic lack of profitability and returns on capital, with ROCE and ROE near zero despite asset growth.
- Market Cap
- ₹360
- P/E Ratio
- 192.0
- P/B Ratio
- 0.82
- ROE
- 0.4%
- ROCE
- 0.3%
- Debt/Equity
- 0.88
- Promoter
- 3.4%
📖 The Story
Evexia Lifecare Ltd appears to be in a prolonged phase of financial stagnation and operational underperformance, with no meaningful revenue or profit growth over the past year and persistently low returns on capital. Management commentary from recent filings indicates routine operational updates and shareholder approvals but no strategic inflection points. The company’s financial trajectory shows flat or declining top-line trends and negligible profitability, with no visible catalysts for improvement.
📰 What's Happening
Recent filings reveal a series of insider trading events where promoter group Shree Saibaba Exim Private Limited has been acquiring shares through open market purchases over September 28–29, 2026, increasing its holding from 6.434% to 6.794% of voting rights. These transactions, filed under SEBI insider trading regulations, are procedural and do not alter control or signal strategic intent. Additionally, the company held its 35th AGM on September 30, 2026, where FY2025-26 financial statements were adopted and new directors appointed, with e-voting results expected within two working days. No major capital raises, M&A, or business pivots were disclosed.
Source: Stock Announcements
📊 Quarterly Results (₹ Cr)
| Metric | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | 26 | 25 | 37 | 31 |
| Operating Profit | 0 | 0 | 1 | 0 |
| OPM % | 0.3% | 0.6% | 2.2% | 1.4% |
| Net Profit | 0 | 0 | 1 | 0 |
| EPS | ₹0.00 | ₹0.00 | ₹0.00 | ₹0.00 |
The quarterly financial data shows a volatile but ultimately flat revenue trend, with June 2026 revenue at ₹31 crore, down from ₹37 crore in March 2026 and ₹26 crore in September 2025, indicating no sustained growth. Operating profits remain marginally positive but highly volatile — ₹1 crore in March 2026 versus near-zero in prior quarters — while net profit and EPS have consistently hovered near zero, underscoring the absence of sustainable earnings. This pattern suggests the company is not scaling operations or achieving margin expansion, despite minor fluctuations in revenue.
🔮 Management Outlook & What's Next
Management has not provided forward-looking guidance or strategic outlook in the latest available filings. The most recent commentary centers on procedural matters such as AGM resolutions and e-voting results, with no discussion of growth targets, margin improvement, or capital allocation strategy beyond routine disclosures. The lack of strategic commentary, combined with persistent financial weakness, suggests limited confidence in near-term recovery or transformation.
Extracted from official company announcements. Not StockFin.ai's opinion.
🏦 Balance Sheet (₹ Cr)
| Item | Mar 2024 | Mar 2025 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Equity Capital | 71 | 188 | 142 | 188 |
| Reserves | 59 | 250 | 195 | 357 |
| Borrowings | 686 | 386 | 502 | 1,222 |
| Total Liabilities | 883 | 920 | 917 | 1,853 |
| Fixed Assets | 11 | 22 | 11 | 14 |
| Investments | 724 | 717 | 749 | 879 |
| Total Assets | 883 | 920 | 917 | 1,853 |
The balance sheet shows a significant increase in total assets from ₹920 crore in March 2025 to ₹1,853 crore in March 2026, driven by a rise in borrowings to ₹1,222 crore from ₹386 crore a year earlier. While equity remains flat at ₹188 crore, the sharp rise in debt indicates aggressive capital deployment, likely funding asset growth. However, this has not translated into improved returns, as ROCE and ROE remain near zero, raising concerns about capital efficiency and potential over-leverage.
💰 Cash Flow Statement (₹ Cr)
| Item | Mar 2024 |
|---|---|
| Operating | +17 |
| Investing | -17 |
| Financing | +1 |
| Net Cash Flow | +0 |
👥 Shareholding Pattern
| Category | Q1FY26 | Q2FY26 | Q3FY26 | Q4FY26 |
|---|---|---|---|---|
| Promoters | 3.5% | 3.4% | 3.5% | 3.4% |
| FII | 0.0% | 0.5% | 0.5% | 0.1% |
| DII | 0.1% | 0.1% | 0.1% | 0.1% |
| Public | 37.0% | 37.3% | 37.4% | 40.8% |
| # Shareholders | 1,51,506 | 1,48,685 | 1,46,498 | 1,44,416 |
Promoter holding has been gradually increasing through recent open market purchases, rising from 3.36% in Q4FY26 to 3.49% in Q3FY26, suggesting modest confidence from insiders. However, institutional investor interest appears to be declining, with FII shareholding dropping from 0.47% in Q2FY26 to 0.12% in Q4FY26, and DII remaining flat at 0.09%. The growing number of shareholders (1,44,416 in Q4FY26) reflects retail dispersion but limited institutional conviction.
⚖️ Peer Comparison — Chemicals
| Company | MCap (₹ Cr) | P/E | ROCE | ROE | D/E |
|---|---|---|---|---|---|
| PIDILITIND | 1.50 L Cr | 56.5 | 33.4% | — | 0.01 |
| SRF | 73,336 | 33.9 | 15.6% | — | 0.36 |
| LINDEINDIA | 54,023 | 98.9 | 17.5% | — | 0.00 |
| FLUOROCHEM | 48,430 | 79.2 | 9.6% | — | 0.34 |
| NAVINFLUOR | 42,306 | 53.5 | 22.2% | — | 0.31 |
| GODREJIND | 34,967 | 29.8 | 9.2% | — | 4.57 |
| HSCL | 34,188 | 42.5 | 20.7% | — | 0.16 |
| AETHER | 22,546 | 95.6 | 13.8% | — | 0.08 |
| DEEPAKNTR | 20,882 | 26.6 | 15.3% | — | 0.26 |
| CASTROLIND | 19,817 | 18.7 | 76.2% | — | 0.00 |
🔗 Peer Stock Analyses
⚠️ Risk Factors
1. Chronic lack of profitability and returns on capital, with ROCE and ROE near zero despite asset growth. 2. Rising leverage, with total borrowings more than tripling in a year, raising solvency concerns if operating performance does not improve. 3. Persistent flat or declining revenue trends with no clear path to margin expansion or top-line recovery. 4. Minimal institutional ownership and low trading liquidity, which could exacerbate price volatility and hinder exit options for investors.
📋 Recent Filings
- 🔴 Insider Trading2026-10-01Evexia Lifecare disclosed an insider trading event involving promoter Shree Saibaba Exim Private Limited acquiring 66,25,997 shares at a value of appr…
- 🟡 Board Meeting2026-09-30Evexia Lifecare Ltd held its 35th AGM on September 30, 2026 via video conference, adopting FY2025-26 financial statements and appointing new directors…
- 🔴 Insider Trading2026-09-29Evexia Lifecare disclosed an insider trading event where promoter group Shree Saibaba Exim purchased 42,42,111 shares at ₹6 per share, increasing its …
- 🔴 Insider Trading2026-09-28Evexia Lifecare disclosed on September 28, 2026 that promoter group Shree Saibaba Exim Private Limited purchased 25,05,000 equity shares, representing…
- Announcement2026-09-26Evexia Lifecare Ltd announced the closure of its trading window effective October 1, 2026, until 48 hours after the unaudited quarterly results for Se…
- 🔴 Insider Trading2026-09-25Evexia Lifecare disclosed that promoter group Shree Saibaba Exim Private Limited acquired 857,000 equity shares on September 24, 2026, representing 0.…
- 🔴 Insider Trading2026-09-23Evexia Lifecare disclosed that promoter group Shree Saibaba Exim purchased 50,33,131 shares at ₹100 each on September 23, 2026, representing 0.268% of…
- 🔴 Insider Trading2026-09-22Evexia Lifecare disclosed an insider purchase of 14,45,000 shares by promoter Shree Saibaba Exim Private Limited on September 22, 2026, representing 0…
- 🔴 Insider Trading2026-09-18Evexia Lifecare disclosed on September 18, 2026 that promoter group Shree Saibaba Exim Private Limited acquired 37,61,527 equity shares representing 0…
- 🔴 Insider Trading2026-09-17Evexia Lifecare disclosed that Shree Saibaba Exim Private Limited, a promoter group entity, acquired 2,93,56,550 equity shares representing 1.563% of …
🧠 Analyst's Read
Evexia Lifecare remains a financially fragile entity with no visible catalysts for operational or financial improvement, marked by stagnant earnings, rising debt, and minimal management guidance. Investors should monitor future disclosures for signs of strategic restructuring, capital raising, or meaningful changes in capital allocation, but until such signals emerge, the company lacks the fundamental indicators of a turnaround or sustainable business model.
Based on filing content and financial data. Not a recommendation.
Read the full analysis
Quarterly trends, balance sheet, cash flow, peer comparison, and AI insights — sign up free to unlock.
Sign Up Free — Unlock Full Analysis2 free AI queries per day.
Data sourced from stock announcements. Analysis generated by StockFin.ai.
For informational purposes only — not investment advice. Updated 2026-10-01.
Editorial & Data Transparency Notice
This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.
📡 Get AI alerts for your stocks — summarized by AI daily
Set up your AI Radar — pick stocks, get daily email summaries of new filings.
Set up AI Radar — FreeFree account · 2 AI queries/day